Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

50.17 +1.12 (+2.29%)
Streaming Delayed Price Updated: 11:09 AM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
News headline image
Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch ↗
The company is planning to soon begin combination studies, testing two of its drugs in weight loss. 
Via Investor's Business Daily
Topics Bankruptcy
News headline image
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy ↗
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly. 
Via Benzinga
News headline image
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock? ↗
Via The Motley Fool
Topics Supply Chain
News headline image
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin? 
Via MarketBeat
News headline image
3 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Veru's Enobosarm Shows Muscle In Wegovy Combo Trial ↗
Via Benzinga
News headline image
This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching. ↗
Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide. 
Via Investor's Business Daily
News headline image
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say ↗
Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular degeneration, and kidney cancer. 
Via Benzinga
News headline image
Novo Nordisk Stock: Is It Still a Smart Buy? ↗
Via The Motley Fool
News headline image
Should You Invest $1,000 in Eli Lilly today? ↗
Via The Motley Fool
News headline image
What's Going On With Novo Nordisk Shares Today? ↗
Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link between GLP-1 weight loss drugs like Ozempic and an increased risk of kidney... 
Via Benzinga
News headline image
Florida Rep. Scott Franklin Bought Up to $15K Worth of Union Pacific Stock ↗
 
Via Benzinga
News headline image
Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target ↗
Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce. 
Via Benzinga
News headline image
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Reasonable Valuation ↗
NOVO-NORDISK (NYSE:NVO) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks. 
Via Chartmill
News headline image
2 Top Stocks to Buy With Less Than $100 ↗
Via The Motley Fool
News headline image
2 Beaten-Down Stocks to Buy on the Dip ↗
Via The Motley Fool
News headline image
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly ↗
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position? 
Via Investor's Business Daily
News headline image
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Candidate for Value Investors ↗
NOVO-NORDISK (NYSE:NVO) offers strong profitability, solid growth, and reasonable valuation, making it a compelling choice for value investors. Its financial health and industry-leading margins add... 
Via Chartmill
News headline image
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market? ↗
Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
3 Surprising Stocks That Have More Than Doubled in 2025 ↗
Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would have predicted. 
Via The Motley Fool
Topics Government
News headline image
Why Novo Nordisk Stock Just Popped ↗
President Trump has good news for Novo Nordisk investors, and more may be on the way. 
Via The Motley Fool
Topics Government World Trade
News headline image
"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy." ↗
Via The Motley Fool
Topics Earnings Economy World Trade
News headline image
8 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Analysts Think These Stocks Could More Than Double in Value
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well. 
Via MarketBeat
Topics World Trade
News headline image
Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dull ↗
Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide... 
Via Stocktwits
News headline image
Novo Nordisk To Sell Wegovy For $199 A Month As Compounding Ban Nears: Retail’s Bullish ↗
The offer will be valid through June 30 and aims to encourage patients who previously used compounded versions of the drug to move to Wegovy. 
Via Stocktwits
News headline image
Did Eli Lilly Just Say Checkmate to Novo Nordisk? ↗
Via The Motley Fool
News headline image
Wegovy, Zepbound Just Got Cheaper: Cigna Sets $200 Monthly Limit For Weight-Loss Drug Users ↗
Cigna’s Evernorth has reached agreements with Eli Lilly and Novo Nordisk to reduce prices for GLP-1 weight-loss drugs Wegovy and Zepbound 
Via Stocktwits
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.